Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MedSIR
Shanghai Henlius Biotech
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gustave Roussy, Cancer Campus, Grand Paris
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Yonsei University
Aurigene Discovery Technologies Limited
M.D. Anderson Cancer Center
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
M.D. Anderson Cancer Center
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Instituto do Cancer do Estado de São Paulo
Canadian Cancer Trials Group
AbbVie
Corcept Therapeutics
Incyte Corporation
Cancer Trials Ireland
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
ARCAGY/ GINECO GROUP
OncoC4, Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
University of Colorado, Denver
Hamilton Health Sciences Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute, Naples
Jazz Pharmaceuticals
University of Florida
Bayer
Regeneron Pharmaceuticals
University of Washington